HPC Binder Designed for Small Tablets
Ashland introduces Klucel EXF Ultra HPC, a low friability, high strength binder.
Ashland has introduced Klucel EXF Ultra HPC, a tablet binder that was developed to enable drug manufacturers to use smaller-size tablets for patients that have challenges swallowing. The announcement was made in an April 30, 2019 press statement.
The hydroxypropyl cellulose (HPC) excipient has exceptional binder efficiency, compressibility, and plasticity with enhanced tablet strength and low friability at usage levels as low as 1–2%, the company reports. The HPC also features an ultra-fine particle size and is designed to enhance hardness and improve friability, which may reduce defect rates.
Ashland reports that the company introduced HPC more than 65 years ago; the Klucel brand has been used for direct compression and dry granulation. The latest version of the HPC was designed to improve manufacturing costs and patient-centric drug delivery by improving tablet binding effectiveness.
Source: Ashland
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
